Global

Feb 18, 2016
Arvind Mani and Sherry O' Quinn outline the prevalence of private payer PLAs in Canada.
Feb 17, 2016
Following the consultation on the future of England's Cancer Drug Fund, Leela Barham reviews what the stakeholders are thinking.
Feb 01, 2016
Pharmaceutical Executive
What the drug industry stands to gain — or lose — from the unthinkable: Britain departing the European Union.
Jan 25, 2016
Kevin E. Noonan asks, what do the biosimilars provisions of the Trans-Pacific Partnership portend for global biologic drug development?
Jan 04, 2016
Gülce Belgin and Donald Macarthur explore the options available for companies to meet the needs of the rare disease population in Turkey.
Nov 30, 2015
The Parliamentary Assembly of the Council of Europe is the latest to clamber aboard the well-filled bandwagon now rumbling and rattling across Europe in an increasingly noisy debate over drug prices. Reflector reports.
Oct 01, 2015
Nick Hicks looks at the challenges of devising a patient advocacy strategy amid the complex political, cultural and regulatory landscape of Russia and CIS.
Sep 03, 2015
By Pharmaceutical Executive Editors
A new trade expo survey predicts that it is full speed ahead for a market now too big to be ignored, writes Cameron Sharp.
Sep 01, 2015
Pharmaceutical Executive
France is a striking example of why the EU is still only "edging towards" a genuine universal system.
native1_300x100
lorem ipsum